z-logo
open-access-imgOpen Access
Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma
Author(s) -
Tomonari Tetsu,
Sato Yasushi,
Tanaka Hironori,
Mitsuhashi Takeshi,
Hirao Akihiro,
Tanaka Takahiro,
Taniguchi Tatsuya,
Okamoto Koichi,
Sogabe Masahiro,
Miyamoto Hiroshi,
Muguruma Naoki,
Takayama Tetsuji
Publication year - 2021
Publication title -
jgh open
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.546
H-Index - 8
ISSN - 2397-9070
DOI - 10.1002/jgh3.12663
Subject(s) - hepatocellular carcinoma , medicine , hazard ratio , gastroenterology , hepatitis b virus , lenvatinib , hepatitis c virus , viral hepatitis , hepatitis b , oncology , confidence interval , immunology , virus , sorafenib
Aim To investigate the therapeutic effect of lenvatinib (LEN) in liver disease etiology, especially nonviral hepatocellular carcinoma (HCC). Methods and Results Sixty‐seven patients with unresectable advanced HCC (u‐HCC) treated with LEN and consisting of 26 hepatitis C virus (HCV), 19 hepatitis B virus (HBV), 11 alcohol, and 11 nonalcoholic steatohepatitis (NASH) cases were retrospectively recruited. Univariate and multivariate Cox proportional hazard models were used to determine predictive factors for survival. The objective response rate in the nonviral (alcohol and NASH) group was higher than that in the viral group (59.1% [13/22] vs. 46.7% [21/45]). Progression‐free survival was significantly longer in the nonviral group than in the viral group (13.7 vs. 6.6 months; hazard ratio [HR] 0.324; 95% confidence interval [CI] 0.174–0.602; P  < 0.01). Similarly, median overall survival (OS) was significantly longer in the nonviral group than in the viral group (not evaluable vs. 15.9 months; HR = 0.277; 95% CI = 0.116–0.662; P  < 0.01). Multivariate analysis revealed that portal vein invasion (HR = 5.327, P  = 0.0025), treatment line (HR = 0.455, P  = 0.023), and etiology (HR = 0.180, P  = 0.00055) were significant independent factors associated with OS in u‐HCC patients treated with LEN. Conclusion Our results suggest that LEN is more effective against nonviral u‐HCC than against viral u‐HCC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here